首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1682538篇
  免费   124590篇
  国内免费   3687篇
耳鼻咽喉   21718篇
儿科学   55457篇
妇产科学   46048篇
基础医学   239555篇
口腔科学   48694篇
临床医学   149349篇
内科学   329884篇
皮肤病学   38628篇
神经病学   130393篇
特种医学   63782篇
外国民族医学   242篇
外科学   256607篇
综合类   38785篇
一般理论   531篇
预防医学   122999篇
眼科学   39952篇
药学   123157篇
  7篇
中国医学   4346篇
肿瘤学   100681篇
  2019年   13268篇
  2018年   19619篇
  2017年   15047篇
  2016年   16442篇
  2015年   18775篇
  2014年   26154篇
  2013年   37916篇
  2012年   52759篇
  2011年   55444篇
  2010年   32747篇
  2009年   30664篇
  2008年   51530篇
  2007年   54812篇
  2006年   55241篇
  2005年   52561篇
  2004年   50761篇
  2003年   48131篇
  2002年   46343篇
  2001年   91748篇
  2000年   93502篇
  1999年   76652篇
  1998年   18804篇
  1997年   16287篇
  1996年   16427篇
  1995年   16655篇
  1994年   15247篇
  1993年   14017篇
  1992年   57364篇
  1991年   55321篇
  1990年   52971篇
  1989年   50770篇
  1988年   46149篇
  1987年   44968篇
  1986年   42231篇
  1985年   40007篇
  1984年   29337篇
  1983年   24872篇
  1982年   13856篇
  1981年   12326篇
  1979年   25476篇
  1978年   17530篇
  1977年   14847篇
  1976年   13805篇
  1975年   14495篇
  1974年   17584篇
  1973年   16892篇
  1972年   15644篇
  1971年   14427篇
  1970年   13416篇
  1969年   12496篇
排序方式: 共有10000条查询结果,搜索用时 18 毫秒
1.
2.
3.
Modified-release opioids are often prescribed for the management of moderate to severe acute pain following total hip and knee arthroplasty, despite recommendations against their use due to increasing concerns regarding harm. The primary objective of this multicentre study was to examine the impact of modified-release opioid use on the incidence of opioid-related adverse events compared with immediate-release opioid use, among adult inpatients following total hip or knee arthroplasty. Data for total hip and knee arthroplasty inpatients receiving an opioid analgesic for postoperative analgesia during hospitalisation were collected from electronic medical records of three tertiary metropolitan hospitals in Australia. The primary outcome was the incidence of opioid-related adverse events during hospital admission. Patients who received modified with or without immediate-release opioids were matched to those receiving immediate-release opioids only (1:1) using nearest neighbour propensity score matching with patient and clinical characteristics as covariates. This included total opioid dose received. In the matched cohorts, patients given modified-release opioids (n = 347) experienced a higher incidence of opioid-related adverse events overall, compared with those given immediate-release opioids only (20.5%, 71/347 vs. 12.7%, 44/347; difference in proportions 7.8% [95%CI 2.3–13.3%]). Modified-release opioid use was associated with an increased risk of harm when used for acute pain during hospitalisation after total hip or knee arthroplasty.  相似文献   
4.
5.
Pharmaceutical Research - The quality testing and approval procedure for most pharmaceutical products is a streamlined process with standardized procedures for the determination of critical quality...  相似文献   
6.
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with intermediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozantinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment.  相似文献   
7.
Neuroscience and Behavioral Physiology - We present here results from analysis of the formation of brain bioelectrical activity in children and adolescents living in the northern region of Russia...  相似文献   
8.
9.
10.
Journal of Pharmacokinetics and Pharmacodynamics - The integration between physiologically-based pharmacokinetics (PBPK) models and pharmacodynamics (PD) models makes it possible to describe the...  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号